Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Short Interest Update

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) saw a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 993,300 shares, a growth of 12.7% from the April 30th total of 881,600 shares. Based on an average daily volume of 86,600 shares, the days-to-cover ratio is currently 11.5 days. Approximately 6.6% of the shares of the company are sold short.

Separately, Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research report on Thursday, July 4th.

NASDAQ:KNSA traded down $0.75 during mid-day trading on Friday, hitting $13.77. 59,060 shares of the company’s stock were exchanged, compared to its average volume of 146,248. Kiniksa Pharmaceuticals has a fifty-two week low of $13.04 and a fifty-two week high of $32.88. The stock’s 50 day moving average is $14.43. The company has a market cap of $753.23 million, a price-to-earnings ratio of -3.95 and a beta of -1.54.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.47). As a group, equities research analysts expect that Kiniksa Pharmaceuticals will post -3.56 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in KNSA. BNP Paribas Arbitrage SA increased its stake in shares of Kiniksa Pharmaceuticals by 1,131.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,685 shares of the company’s stock valued at $48,000 after acquiring an additional 2,467 shares in the last quarter. Barclays PLC increased its stake in shares of Kiniksa Pharmaceuticals by 25.7% in the 4th quarter. Barclays PLC now owns 3,054 shares of the company’s stock valued at $86,000 after acquiring an additional 624 shares in the last quarter. New York State Common Retirement Fund bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $107,000. Rhumbline Advisers bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $223,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $268,000. Institutional investors own 29.76% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Read More: Marijuana Stocks

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.